NIH funded research involving trastuzumab (marketed by Roche under the trade name Herceptin)

13 December 2010

Drugs@FDA
Drug Name(s) HERCEPTIN (Brand Name Drug)
FDA Application No. (BLA) 103792
Active Ingredient(s) TRASTUZUMAB
Company GENENTECH (Roche acquired a majority ownership in 1990, and full ownership in March 2009.)
Original Approval or Tentative Approval Date September 25, 1998

What is Herceptin? How does it work?

Continue Reading

Uncategorized

Statements by KEI and others on NIH rejection of Fabrazyme March-In Request

For background on the Fabrazyme case, see: https://www.keionline.org/fabrazyme

The following statements were made today by civil society on the NIH rejection of the Fabrazyme March-in Request Petition. Contact Judit Rius at judit.rius@keionline.org if your organization would like to submit an statement.

Statement by James Love, Director of Knowledge Ecology International (KEI) (Contact: 1.202.361.3040)

Continue Reading

Microsoft, Gates Foundation Timeline

November 29, 2010 Revised January 4, 2011 Introduction This timeline contains a number of selected data points concerning Microsoft and the Bill and Melinda Gates Foundation (BMGF). The motivations for this timeline, which features entries for both Microsoft and the… Continue Reading

A KEI note to Library of Congress about ACTA text

From: James Love
To: Michele Woods
Cc: Nancy Weiss
Subject: Some examples of US inconsistency with ACTA
Date: Fri, 12 Nov 2010 07:29:09 -0500

This note cites several areas where US law is plainly inconsistent with
ACTA.

In addition, in a separate analysis,I have called attention to proposed
legislation in USA on orphan copyrighted works that are very
inconsistent with ACTA provisions on remedies.
https://www.keionline.org/node/980

Some examples of inconsistencies between ACTA and US law

Continue Reading

Uncategorized

SCCR 21: Initial impressions from day 1

The 21st session of the WIPO Standing Committee on Copyright and Related Rights (SCCR) commenced its work at 10:33 AM on Monday, 8 November 2010.

This unusually quick start is perhaps indicative of Member States’ commitment to examine the three substantive agenda items up for consideration during this five day negotiation; these three issues include: 1) protection of broadcasting organizations, 2) protection of audiovisual performances and 3) limitations and exceptions.

Continue Reading